Belite Bio (BLTE) Research & Development (2022 - 2026)
Belite Bio (BLTE) posted quarterly Research & Development of $15.7 million for Q1 2026, up 66.68% year-over-year from $9.4 million in Q1 2025, and down 99.89% quarter-over-quarter from $14.6 billion in Q4 2025.
Belite Bio (BLTE) Research & Development (2022 - 2026) Analysis & Trends
Belite Bio's Research & Development history runs 5 years deep, the most recent figure standing at $15.7 million for Q1 2026.
- In Q1 2026, Research & Development rose 66.68% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $36.0 billion (up 55.26% YoY), while the FY2025 annual figure was $45.4 million, up 51.56% from the prior year.
- Research & Development for Q1 2026 stood at $15.7 million, down from $14.6 billion in the prior quarter.
- The five-year high for Research & Development was $14.6 billion in Q4 2025, with the low at $4.9 million in Q4 2023.
- The 5-year median for Research & Development is $5.6 billion (2023), against an average of $5.0 billion.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 149097.86% in 2024, then sank 99.86% in 2025.
- Belite Bio's Research & Development stood at $5.2 million in 2022, then slipped by 6.97% to $4.9 million in 2023, then surged by 149097.86% to $7.3 billion in 2024, then soared by 101.6% to $14.6 billion in 2025, then tumbled by 99.89% to $15.7 million in 2026.
- Business Quant data shows BLTE's Research & Development at $15.7 million in Q1 2026, $14.6 billion in Q4 2025, and $10.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 15.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.66 Mn |
| Dec 31, 2025 | 14.62 Bn |
| Sep 30, 2025 | 10.31 Bn |
| Jun 30, 2025 | 11.05 Bn |
| Mar 31, 2025 | 9.40 Mn |
| Dec 31, 2024 | 7.25 Bn |
| Sep 30, 2024 | 6.84 Bn |
| Jun 30, 2024 | 9.08 Bn |
| Mar 31, 2024 | 6.77 Bn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 8.74 Mn |
| Jun 30, 2023 | 5.52 Bn |
| Mar 31, 2023 | 5.72 Bn |
| Dec 31, 2022 | 5.23 Mn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.58 Bn |